PEOPLE - Osiris Therapeutics (US) forms new senior management team:
This article was originally published in Clinica
Executive Summary
US company Osiris Therapeutics has formed a senior management team which will focus on the commercialisation of its adult stem cell products. It includes Dr Annemarie Moseley as senior vice-president of clinical and regulatory affairs; Dr Daniel Marshak, senior vice-president and chief scientific officer; John Coker, vice-president and chief financial officer, secretary and treasurer; Dr Stewart Craig, vice-president of development and operations; Dr Robert Deans, vice-president of applied research; Dr Stephen Gordon, vice-president of advanced technology management; and Kenneth Moseley, vice-president of patents and business development.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.